Sulfadoxine-pyrimethamine at 4-week intervals

Phase 3Small molecule

Sulfadoxine-pyrimethamine at 4-week intervals is one of 3 small molecule programs targeting Preterm Birth. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Preterm BirthActive, not recruiting

Preterm BirthPhase 3

Active, not recruiting

Competition

Competitive Landscape

3 competitors in Preterm Birth

#DrugCompanyPhaseTrials

Azulfidine

Pfizer

Phase 2

1 2

Sulfadoxine-pyrimethamine at 4-week intervals

TTampere University

Phase 3

1 3

Tractocile

GSK

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 3Active, not recruiting

Preterm Birth

NCT00131235

Clinical

Trials by Indication[1]

Preterm Birth1 trial

Gestational Sulfadoxine-pyrimethamine and Azithromycin Treatment to Prevent Preterm Birth

Active, not recruiting·TTampere University·Phase 3·NCT00131235·1,320 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Sulfadoxine-pyrimethamine at 4-week intervals. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Sulfadoxine-pyrimethamine at 4-week intervals compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Sulfadoxine-pyrimethamine at 4-week intervals. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Tampere University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: TTampere University

Sulfadoxine-pyrimethamine at 4-week intervals

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Preterm Birth1 trial

References

Drug Info

Quick Facts

Related News